Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
								
																		
									
										
											Công thức hóa học
										
										
											
																						C8H15NO2																					
									 
																											
																		
									
																											
																		
									
										
											Monoisotopic mass 
										
										
											157.110278729										
									 
																											
									
																		
									
										
											InChI 
										
										
											InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-										
									 
																		
																		
										
											InChI Key 
										
										
											InChIKey=GYDJEQRTZSCIOI-LJGSYFOKSA-N										
									 
																											
																		
										
											IUPAC Name 
										
										
											(1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid										
									 
																											
																		
										
											Traditional IUPAC Name 
										
										
											cyklokapron										
									 
																											
									
																		
										
											SMILES 
										
										
											NC[C@H]1CC[C@@H](CC1)C(O)=O										
									 
																		
																		
									
																		
																		
																		
																		
																		
										
											Độ hòa tan
										
										
											1.67E+005 mg/L										
									 
																											
																		
																											
																		
																											
																		
										
											pKa (strongest acidic) 
										
										
											4.56										
									 
																											
																		
										
											pKa (Strongest Basic) 
										
										
											10.22										
									 
																											
																		
																											
																		
										
											Refractivity 
										
										
											41.9 m3·mol-1
										
									 
																			  
		  
																		
																											
																		
																		
									
																		
																		
																		
																		
																		
																		
																		
											  
		  
								 
							 	
														
															
								 Dược Lực Học : 
								
									Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).									
							
														
															
								 Cơ Chế Tác Dụng : 
								
									Antifibrinolytic hemostatic used in severe hemorrhage. [PubChem]								
								
									Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.								
							
														
															
								 Dược Động Học  : 
								
									▧ Absorption : 
Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
▧ Volume of Distribution : 
* 9 to 12 L
▧ Protein binding : 
The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).
▧ Metabolism : 
Only a small fraction of the drug is metabolized (less than 5%).
▧ Route of Elimination : 
Urinary excretion is the main route of elimination via glomerular filtration.
▧ Half Life : 
Biological half-life in the joint fluid is about 3 hours.
▧ Clearance : 
* 110 - 116 mL/min								
	
							 
														
														
								 Độc Tính : 
								
									Oral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.									
							
														
							
																					
								 Chỉ Định : 
								
									For use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.								
							
	
														
									
							
							
							
							
								
								 Liều Lượng & Cách Dùng : 
								
									Solution - Intravenous
Tablet - Oral								
							
	
							
														
														
							
																						
								 Dữ Kiện Thương Mại 
								
																											
										
											Giá thị trường
										
										
											
																							- 
													
													Giá bán buôn : USD >1.3 Đơn vị tính : tablet 
- 
													
													Giá bán buôn : USD >1.97 Đơn vị tính : g 
- 
													
													Giá bán buôn : USD >8.8 Đơn vị tính : ml 
 
									 
																		
																											
										
											Nhà Sản Xuất
										
										
											
																							- 
													
													Sản phẩm biệt dược : Cyclo-F 
- 
													
													Sản phẩm biệt dược : Cyklokapron 
- 
													
													Sản phẩm biệt dược : Espercil 
- 
													
													Sản phẩm biệt dược : Femstrual 
- 
													
													Sản phẩm biệt dược : Lysteda 
- 
													
													Sản phẩm biệt dược : Rikavarin 
- 
													
													Sản phẩm biệt dược : Transamin 
- 
													
													Sản phẩm biệt dược : Transcam 
- 
													
													Sản phẩm biệt dược : Traxyl 
 
									 
																		
																											
											  
		  
								 
							 	
							
							
														
							
						
							
																													
								 Tài Liệu Tham Khảo Thêm 
								
																		
																		
																		
										
											National Drug Code Directory